• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

同时对多个结局进行综合,并将治疗效果映射到一个共同的尺度上。

Simultaneous multioutcome synthesis and mapping of treatment effects to a common scale.

机构信息

School of Social & Community Medicine, University of Bristol, Bristol, UK.

School of Social & Community Medicine, University of Bristol, Bristol, UK.

出版信息

Value Health. 2014 Mar;17(2):280-7. doi: 10.1016/j.jval.2013.12.006.

DOI:10.1016/j.jval.2013.12.006
PMID:24636388
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3991420/
Abstract

OBJECTIVES

A new method is presented for both synthesizing treatment effects on multiple outcomes subject to measurement error and estimating coherent mapping coefficients between all outcomes. It can be applied to sets of trials reporting different combinations of patient- or clinician-reported outcomes, including both disease-specific measures and generic health-related quality-of-life measures. It is underpinned by a structural equation model that includes measurement error and latent common treatment effect factor. Treatment effects can be expressed on any of the test instruments that have been used.

METHODS

This is illustrated in a synthesis of eight placebo-controlled trials of TNF-α inhibitors in ankylosing spondylitis, each reporting treatment effects on between two and five of a total six test instruments.

RESULTS

The method has advantages over other methods for synthesis of multiple outcome data, including standardization and multivariate normal synthesis. Unlike standardization, it allows synthesis of treatment effect information from test instruments sensitive to different underlying constructs. It represents a special case of previously proposed multivariate normal models for evidence synthesis, but unlike the former, it also estimates mappings. Combining synthesis and mapping as a single operation makes more efficient use of available data than do current mapping methods and generates treatment effects that are consistent with the mappings. A limitation, however, is that it can only generate mappings to and from those instruments on which some trial data exist.

CONCLUSIONS

The method should be assessed in a wide range of data sets on different clinical conditions, before it can be used routinely in health technology assessment.

摘要

目的

提出了一种新的方法,用于综合多个受测量误差影响的结局的治疗效果,并估计所有结局之间的一致性映射系数。它可应用于报告患者或临床医生报告的结局的不同组合的一系列试验,包括特定疾病的测量指标和通用健康相关生活质量测量指标。它基于一个结构方程模型,包括测量误差和潜在的共同治疗效果因素。治疗效果可以在使用过的任何测试仪器上表示。

方法

以八项 TNF-α 抑制剂治疗强直性脊柱炎的安慰剂对照试验的综合为例,每项试验报告了六种测试仪器中的两种至五种之间的治疗效果。

结果

该方法在综合多个结局数据方面优于其他方法,包括标准化和多元正态综合。与标准化不同,它允许从对不同潜在结构敏感的测试仪器中综合治疗效果信息。它代表了以前提出的证据综合多元正态模型的一个特例,但与前者不同的是,它还估计了映射。将综合和映射作为单一操作进行,可以比当前的映射方法更有效地利用现有数据,并生成与映射一致的治疗效果。然而,一个限制是,它只能生成与存在一些试验数据的仪器之间的映射。

结论

在常规用于卫生技术评估之前,应在不同临床条件的广泛数据集上评估该方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6f/3991420/458d6d9063ce/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6f/3991420/458d6d9063ce/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6f/3991420/458d6d9063ce/gr1.jpg

相似文献

1
Simultaneous multioutcome synthesis and mapping of treatment effects to a common scale.同时对多个结局进行综合,并将治疗效果映射到一个共同的尺度上。
Value Health. 2014 Mar;17(2):280-7. doi: 10.1016/j.jval.2013.12.006.
2
Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.阿达木单抗、依那西普和英夫利昔单抗治疗强直性脊柱炎:系统评价与经济学评估
Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. doi: 10.3310/hta11280.
3
Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal.戈利木单抗治疗强直性脊柱炎:NICE 单技术评估
Pharmacoeconomics. 2013 May;31(5):415-25. doi: 10.1007/s40273-013-0049-2.
4
Mapping clinical outcomes to generic preference-based outcome measures: development and comparison of methods.将临床结局映射到通用偏好为基础的结局测量指标:方法的制定与比较。
Health Technol Assess. 2020 Jun;24(34):1-68. doi: 10.3310/hta24340.
5
The Comparative Safety of TNF Inhibitors in Ankylosing Spondylitis-a Meta-Analysis Update of 14 Randomized Controlled Trials.TNF 抑制剂在强直性脊柱炎中安全性的比较-14 项随机对照试验的荟萃分析更新。
Clin Rev Allergy Immunol. 2018 Apr;54(2):234-243. doi: 10.1007/s12016-017-8623-6.
6
Indirect comparison of the effects of anti-TNF biological agents in patients with ankylosing spondylitis by means of a mixed treatment comparison performed on efficacy data from published randomised, controlled trials.通过对已发表的随机对照试验的疗效数据进行混合治疗比较,间接比较抗 TNF 生物制剂在强直性脊柱炎患者中的疗效。
J Med Econ. 2012;15(3):473-80. doi: 10.3111/13696998.2012.660255. Epub 2012 Feb 16.
7
The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.强直性脊柱炎患者对抗肿瘤坏死因子(抗TNF)治疗的未满足需求。
Rheumatology (Oxford). 2005 Oct;44(10):1277-81. doi: 10.1093/rheumatology/keh713. Epub 2005 Aug 16.
8
Efficacy of antitumor necrosis factor(α) agents on patients with ankylosing spondylitis.抗肿瘤坏死因子(α)药物治疗强直性脊柱炎的疗效。
Am J Med Sci. 2013 Dec;346(6):455-61. doi: 10.1097/MAJ.0b013e3182926a23.
9
[New results from studies of therapy of ankylosing spondylitis with infliximab].[英夫利昔单抗治疗强直性脊柱炎的研究新成果]
Z Rheumatol. 2003 Apr;62(2):108-9. doi: 10.1007/s00393-003-0501-3.
10
Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.通过抑制肿瘤坏死因子α治疗强直性脊柱炎。
N Engl J Med. 2002 May 2;346(18):1349-56. doi: 10.1056/NEJMoa012664.

引用本文的文献

1
Analyzing quality of life among people with opioid use disorder from the National Institute on Drug Abuse Data Share initiative: implications for decision making.分析来自国家药物滥用研究所数据共享计划的阿片类药物使用障碍患者的生活质量:对决策的影响。
Qual Life Res. 2024 Oct;33(10):2783-2796. doi: 10.1007/s11136-024-03729-6. Epub 2024 Aug 8.
2
Classifying information-sharing methods.分类信息共享方法。
BMC Med Res Methodol. 2021 May 22;21(1):107. doi: 10.1186/s12874-021-01292-z.
3
Uptake of methodological advances for synthesis of continuous and time-to-event outcomes would maximize use of the evidence base.

本文引用的文献

1
Multivariate meta-analysis of mixed outcomes: a Bayesian approach.混合结局的多变量荟萃分析:贝叶斯方法。
Stat Med. 2013 Sep 30;32(22):3926-43. doi: 10.1002/sim.5831. Epub 2013 Apr 30.
2
Bayesian multivariate meta-analysis with multiple outcomes.贝叶斯多元荟萃分析与多个结局。
Stat Med. 2013 Jul 30;32(17):2911-34. doi: 10.1002/sim.5745. Epub 2013 Feb 6.
3
Mapping to obtain EQ-5D utility values for use in NICE health technology assessments.用于 NICE 健康技术评估的 EQ-5D 效用值映射。
吸收方法学进展来综合连续型和生存型结局数据,可以最大限度地利用证据基础。
J Clin Epidemiol. 2020 Aug;124:94-105. doi: 10.1016/j.jclinepi.2020.05.010. Epub 2020 May 12.
4
Evaluating construct equivalence of youth depression measures across multiple measures and multiple studies.评估多个测量工具和多项研究中青少年抑郁测量工具的结构等效性。
Psychol Assess. 2019 Sep;31(9):1154-1167. doi: 10.1037/pas0000737. Epub 2019 Jul 1.
5
Using Parameter Constraints to Choose State Structures in Cost-Effectiveness Modelling.使用参数约束选择成本效益建模中的状态结构。
Pharmacoeconomics. 2017 Sep;35(9):951-962. doi: 10.1007/s40273-017-0501-9.
6
Multiple imputation for harmonizing longitudinal non-commensurate measures in individual participant data meta-analysis.个体参与者数据荟萃分析中对纵向非一致性测量进行调和的多重填补。
Stat Med. 2015 Nov 20;34(26):3399-414. doi: 10.1002/sim.6562. Epub 2015 Jun 21.
7
Simultaneous synthesis of treatment effects and mapping to a common scale: an alternative to standardisation.治疗效果的同步合成及映射到共同量表:标准化的替代方法
Res Synth Methods. 2015 Mar;6(1):96-107. doi: 10.1002/jrsm.1130. Epub 2015 Jan 23.
Value Health. 2013 Jan-Feb;16(1):202-10. doi: 10.1016/j.jval.2012.10.010.
4
Which health-related quality-of-life outcome when planning randomized trials: disease-specific or generic, or both? A common factor model.规划随机试验时应选择哪种与健康相关的生活质量结局:疾病特异性的还是一般性的,或者两者都选?一个共同因素模型。
Value Health. 2013 Jan-Feb;16(1):185-94. doi: 10.1016/j.jval.2012.09.012.
5
Mapping from disease-specific to generic health-related quality-of-life scales: a common factor model.从疾病特异性量表到通用健康相关生活质量量表的映射:共同因素模型。
Value Health. 2013 Jan-Feb;16(1):177-84. doi: 10.1016/j.jval.2012.07.003. Epub 2012 Sep 25.
6
Estimating within-study covariances in multivariate meta-analysis with multiple outcomes.多元荟萃分析中多重结局的组内协方差估计
Stat Med. 2013 Mar 30;32(7):1191-205. doi: 10.1002/sim.5679. Epub 2012 Dec 3.
7
Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials.证据综合决策 2:用于随机对照试验的成对和网络荟萃分析的广义线性建模框架。
Med Decis Making. 2013 Jul;33(5):607-17. doi: 10.1177/0272989X12458724. Epub 2012 Oct 26.
8
The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.多奈哌齐、加兰他敏、利伐斯的明和美金刚治疗阿尔茨海默病的有效性和成本效果(技术评估第 111 号回顾):系统评价和经济模型。
Health Technol Assess. 2012;16(21):1-470. doi: 10.3310/hta16210.
9
A practical introduction to multivariate meta-analysis.实用多元荟萃分析导论。
Stat Methods Med Res. 2013 Apr;22(2):133-58. doi: 10.1177/0962280211432219. Epub 2012 Jan 23.
10
Evaluation of Ankylosing Spondylitis Quality of Life questionnaire: responsiveness of a new patient-reported outcome measure.评估强直性脊柱炎生活质量问卷:一种新的患者报告结局测量工具的反应性。
Rheumatology (Oxford). 2012 Apr;51(4):707-14. doi: 10.1093/rheumatology/ker377. Epub 2011 Dec 16.